Printer Friendly

Juridical Foundation The Chemo-Sero-Therapeutic Research Institute obtains United States patent.

Juridical Foundation The Chemo-Sero-Therapeutic Research Institute (Kumamoto-shi, Japan) has patented a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48 kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention. (US 7,326,543)
COPYRIGHT 2008 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Jan 1, 2008
Previous Article:Cardica Receives $2 Million Payment From Cook Medical for Successful Completion of Multiple Milestones.
Next Article:Takara Bio obtains United States patent.

Related Articles
Altarex licenses United States issued patents for autoimmune disease therapy.
Advanced Life Sciences patents anti-hepatitis B virus drug.
Early detection breast cancer patent licensed by Samaritan.
Geron and University of Wisconsin resolve lawsuit and sign new license agreement.
Advanced Research and Technology obtains United States patent.
Stelic Announces Research Activities, Business Strategy for the Current Fiscal Year.
Sovereignty and Possession in the English New World: The Legal Foundations of Empire, 1576-1640.
Epeius Biotechnologies Awarded United States Patent for Targeted Injectable Gene Delivery In Vivo.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters